Rapport Therapeutics (RAPP) CEO Ceesay Sells $64K of Stock

Inside Abraham Ceesay's Rapport Therapeutics Trade

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Chief Executive Officer Abraham Ceesay sold 2,210 shares of the company on October 21, 2026, according to a Form 4 filing with the SEC. The shares were sold at an average price of $29.16, for a total value of $64,447.58. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Ceesay directly held 450,035 shares, marking a 0.49% reduction in his holdings.

RAPP Rapport Therapeutics, Inc.

$26.53 ▼ -5.62% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Other Institutional Activity in Rapport Therapeutics

Other large funds have adjusted their positions in the clinical-stage biopharmaceutical company recently. Trv Gp V, LLC reduced its holdings by 854,814 shares, ending the period with 6,280,525 shares worth about $162,854,015. Arch Venture Management, Llc kept its stake unchanged at 3,728,738 shares valued at roughly $96,686,177. Capital International Investors trimmed its position by 175,962 shares to hold 2,921,958 shares worth approximately $75,766,371. Cormorant Asset Management, LP lowered its stake by 299,881 shares, finishing with 2,657,521 shares valued at about $68,909,520. Meanwhile, Sofinnova Investments, Inc. maintained its holding at 1,904,408 shares worth roughly $49,381,300.

Rapport Therapeutics, Inc. Stock Up 3.5%

Rapport Therapeutics shares closed at $25.06 on the transaction date and recently traded around $26.53 as of October 23, 2026. The stock sits below its 50-day moving average of $39.48 and well below its 52-week high of $52.93, while trading roughly 11.7% above its 52-week low of $23.75.

Recent Earnings

The company reported trailing-twelve-month revenue of $20.0 million and an EPS of -$3.03. Its return on equity stood at -40.0%. Rapport Therapeutics has scheduled its next earnings release for November 5, 2026.

Insider Buying and Selling at Rapport Therapeutics, Inc.

Insider transactions around the same time included CFO Troy A. Ignelzi purchasing 5,500 shares on October 21, 2026, for $143,550. Later, on October 22, 2026, director John Maraganore bought 9,411 shares for $248,890.83, director Steven M Paul acquired 35,714 shares for $974,277.92, and director Wendy B. Young bought 3,789 shares for $99,991.71.

Analysts Set New Price Targets

Analyst coverage ahead of the trade included HC Wainwright & Co. reiterating a Buy rating with a $66.0 target on October 20, 2026. BTIG maintained a Buy rating while lifting its target from $75.0 to $89.0 on the same day. On October 21, 2026, Jones Trading maintained a Buy rating and raised its target from $50.0 to $82.0. Wells Fargo maintained an Overweight rating and adjusted its target from $51.0 to $50.0, while Guggenheim maintained a Buy rating and raised its target from $65.0 to $70.0. Overall, the company carries a consensus strong buy rating with a mean price target of $69.40 across 15 analyst opinions.

About Rapport Therapeutics

Based in Boston, Massachusetts, Rapport Therapeutics focuses on discovering and developing small molecule medicines for central nervous system disorders. The clinical-stage biopharmaceutical firm employs 84 people and operates within the healthcare sector.

Bottom Line

Investors are keeping an eye on upcoming financial updates, including the scheduled earnings report on November 5, 2026. SEC Form 4 filings will continue to provide updates on executive and director ownership changes.